Abbie Celniker

Abbie Celniker joined Third Rock Ventures as Partner in 2016. Dr. Celniker brings more than 20 years of proven expertise in leading protein therapeutic discovery and development companies and programs to Eleven Biotherapeutics. Prior to joining Eleven, Abbie was CEO of Taligen Therapeutics, a biotechnology company focused on complement system regulation, which was acquired by Alexion Pharmaceuticals in January 2011. Prior to Taligen, Dr. Celniker was global head of biologics at Novartis, where she oversaw the biologics division, forged strategic alliances, and led internal discovery and development to build the pipeline. Prior to Novartis, Dr. Celniker spent more than six years at Millennium Pharmaceuticals as senior vice president, R&D strategy and operations and head of biotherapeutics and pharmaceutical sciences. Previously, she held senior research and development leadership roles with Wyeth BioPharma (Genetics Institute) and Genentech. Dr. Celniker holds a Ph.D. in Molecular Biology from the University of Arizona and a B.A. in Biology from the University of California, San Diego.